Wellington Management Group
AVDL

Wellington Management Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Wellington Management Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-554,493
Closed -$8.47M – 1932
2025
Q3 		$8.47M Buy
554,493
+516,187
+1,348% +$6.72M ﹤0.01% 1306
2025
Q2 		$339K Buy
+38,306
New +$337K ﹤0.01% 1865
2024
Q4 		– Sell
-48,236
Closed -$633K – 1943
2024
Q3 		$633K Buy
+48,236
New +$735K ﹤0.01% 1785

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group's AVDL Position: Q4 2025 in Review

Wellington Management Group sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 554,493 shares — an estimated $8.47M sold.

Wellington Management Group first reported a position in AVDL in Q3 2024 and held it in 3 quarters. The position peaked at $8.47M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Wellington Management Group reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wellington Management Group sold 554,493 Avadel Pharmaceuticals shares in Q4 2025, an estimated $8.47M.
  • Wellington Management Group first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Wellington Management Group's Avadel Pharmaceuticals position peaked at $8.47M in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Wellington Management Group's 13F filing for Q4 2025, filed 17 Feb 2026.